FDA Approves Daurismo (glasdegib) for Patients with Acute Myeloid Leukemia
FDA Approves Daurismo (glasdegib) for Patients with Acute Myeloid Leukemia Print this page November 21, 2018 — The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75… Read More »